



Assoc. Prof. Dr. Eva Roblegg is pharmaceutical scientist at the Institute of Pharmaceutical Sciences, Deputy Head of the Department Pharmaceutical Technology and Biopharmacy at the Karl-Franzens University, Graz, Austria (<http://www.uni-graz.at>) and key researcher at the Research Center Pharmaceutical Engineering (<http://www.rcpe.at/>). After a research visit at the Johann Wolfgang Goethe-University (Frankfurt, Germany) she finished her PhD in 2000. She took a maternity leave, spent two years in pharmacy and was approbated as pharmacist in 2005. In 2006, she joined the Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy in Graz as post-doctoral fellow and later on as Assistant Professor. In 2012 she spent 8 months as guest scientist at the Saarland University, Department Biopharmaceutics and Pharmaceutical Technology and at the Helmholtz Institute for Pharmaceutical Research Saarland, Drug Delivery Department (Saarbrücken, Germany) and was awarded with the Galenus Technology Prize 2013. She finished her habilitation in May 2014; in 2015 and 2018 she held Guest Professorships at the University of Ljubljana, Slovenia and at Stanford University, USA. The main focus of her research are biological barriers, in particular the oral cavity and the small intestine. In parallel, she is interested in finding oral multifunctional (nano-) drug delivery systems and developing advanced manufacturing methods such as (nano)extrusion and (nano)printing. She has (co-) supervised more than 30 diploma theses, 5 PhD students and 2 PostDocs and her publication record encompasses over 60 peer-reviewed publications and several book chapters (h-index 18). She holds two patents in the area of pharmaceutical manufacturing and has received grant support from e.g., Austrian Research Promotion Agency (FFG), EU, OECD and several industry partners.

Currently, she is Head of the Doctoral School of Pharmaceutical Sciences and Member of the Curricula Committee. Since 2009 she is also OECD Member of the Steering Group 7 for Alternative Testing Models. She serves on the editorial board of NanoTexLetters and acts as reviewer for journals such as, Nature Communications, Small, EJPB, IJP, DDIP, CLOI, Particle and Fiber Tox, Nanomedicine: Nanotechnology, Biology, and Medicine, etc..